Titlebook: Antiphospholipid Syndrome; Current Research Hig Doruk Erkan,Michael D. Lockshin Book 2017 Springer International Publishing AG 2017 antipho

notification

Affectation

latest state-of-the-art information about evidence-based praThis new edition is a comprehensive and updated resource on antiphospholipid syndrome (APS), which is an autoimmune disorder. In APS, the body recognizes certain normal components of blood and/or cell membranes as foreign substances and pro

JOT

Charge in Electromagnetic Wave,of clinical manifestations exists, and thrombosis may be multifactorial. A standard definition of APS is challenging. Although data on epidemiology of APS are limited, being based on small scale studies or studies with methodological limitations, this chapter gives the best synthesis possible today.

CUMB

S. Ciulli,C. Pomponiu,I. Sabba Stefanescumanagement of some manifestations of APS remains empirical and with limited evidence-based data. In this chapter, together with a concise literature review, each situation is illustrated by a real clinical case followed by an expert discussion. Potential future treatment strategies for aPL-positive patients are also discussed.

cipher

S. Ciulli,C. Pomponiu,I. Sabba Stefanescues (aPL) with/without aPL-related clinical symptoms. Since 2010, through the dedication APS ACTION members, collaborative international projects are underway. This chapter provides a summary of the organization’s structure, ongoing research efforts, and recent accomplishments and discusses future directions.

Injunction

含沙射影

Treatment of Non-criteria Manifestations in Antiphospholipid Syndromemanagement of some manifestations of APS remains empirical and with limited evidence-based data. In this chapter, together with a concise literature review, each situation is illustrated by a real clinical case followed by an expert discussion. Potential future treatment strategies for aPL-positive patients are also discussed.

filial

Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION)es (aPL) with/without aPL-related clinical symptoms. Since 2010, through the dedication APS ACTION members, collaborative international projects are underway. This chapter provides a summary of the organization’s structure, ongoing research efforts, and recent accomplishments and discusses future directions.

Needlework

Disease and Risk Measurement Criteria in Antiphospholipid Syndromermanent damage may occur, a damage index for APS (DIAPS) has been developed and validated. The consequences of permanent damage due to thrombosis in APS patients decrease the health-related quality of life (HRQoL).

HEW